Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027
Ultragenyx Pharmaceutical Inc. (RARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contacts Ultragenyx Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com Media Jess Rowlands media@ultragenyx.com Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027 Third quart
How this was made
The 30-second read
Why it matters
The company’s reaffirmed guidance and expense reductions provide a fresh catalyst that could move the stock in the near term.
Market read
Primary earnings release with new guidance and FDA approvals; high relevance for traders targeting biotech micro‑caps.
What to watch
Potential execution risk on commercial launch of GENGLYCOS and FAYUVI and the impact of restructuring charges in Q4.
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027
Third-quarter revenue and the net loss improved from the prior-year period, supported by product revenue growth and lower research and development expense, while the company remained loss-making, held a stockholders' deficit, and initiated substantial headcount and program reductions.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenues - Three Months Ended September 30, 2026GAAP | $173M | – | – |
| Product sales - Three Months Ended September 30, 2026GAAP | $105M | – | – |
| Royalty revenue - Three Months Ended September 30, 2026GAAP | $68M | – | – |
| Cost of sales - Three Months Ended September 30, 2026GAAP | $32M | – | – |
| Research and development - Three Months Ended September 30, 2026GAAP | $154M | – | – |
| Selling, general and administrative - Three Months Ended September 30, 2026GAAP | $97M | – | – |
| Total operating expenses - Three Months Ended September 30, 2026GAAP | $283M | – | – |
| Loss from operations - Three Months Ended September 30, 2026GAAP | −$110M | – | – |
| Non-cash interest expense on liabilities for sales of future royalties - Three Months Ended September 30, 2026GAAP | −$20M | – | – |
| Other income, net - Three Months Ended September 30, 2026GAAP | $3M | – | – |
| Loss before income taxes - Three Months Ended September 30, 2026GAAP | −$127M | – | – |
| Benefit from (provision for) income taxes - Three Months Ended September 30, 2026GAAP | $9M | – | – |
| Net loss - Three Months Ended September 30, 2026GAAP | −$118M | – | – |
| Net loss per share, basic and diluted - Three Months Ended September 30, 2026GAAP | $(1.16) per share | – | – |
| Shares used in computing net loss per share, basic and diluted - Three Months Ended September 30, 2026GAAP | 102.1M | – | – |
| Non-cash stock-based compensation - Three Months Ended September 30, 2026GAAP | $34M | – | – |
| Restructuring expense - Three Months Ended September 30, 2026GAAP | — | – | – |
| Total revenues - Nine Months Ended September 30, 2026GAAP | $523M | – | – |
| Product sales - Nine Months Ended September 30, 2026GAAP | $306M | – | – |
| Royalty revenue - Nine Months Ended September 30, 2026GAAP | $217M | – | – |
| Cost of sales - Nine Months Ended September 30, 2026GAAP | $96M | – | – |
| Research and development - Nine Months Ended September 30, 2026GAAP | $508M | – | – |
| Selling, general and administrative - Nine Months Ended September 30, 2026GAAP | $273M | – | – |
| Total operating expenses - Nine Months Ended September 30, 2026GAAP | $877M | – | – |
| Loss from operations - Nine Months Ended September 30, 2026GAAP | −$354M | – | – |
| Non-cash interest expense on liabilities for sales of future royalties - Nine Months Ended September 30, 2026GAAP | −$63M | – | – |
| Other income, net - Nine Months Ended September 30, 2026GAAP | $15M | – | – |
| Loss before income taxes - Nine Months Ended September 30, 2026GAAP | −$402M | – | – |
| Benefit from (provision for) income taxes - Nine Months Ended September 30, 2026GAAP | $7M | – | – |
| Net loss - Nine Months Ended September 30, 2026GAAP | −$395M | – | – |
| Net loss per share, basic and diluted - Nine Months Ended September 30, 2026GAAP | $(3.89) per share | – | – |
| Shares used in computing net loss per share, basic and diluted - Nine Months Ended September 30, 2026GAAP | 101.6M | – | – |
| Non-cash stock-based compensation - Nine Months Ended September 30, 2026GAAP | $98M | – | – |
| Restructuring expense - Nine Months Ended September 30, 2026GAAP | $30M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| CRYSVITA - Total RevenueConsistent with expected ordering patterns. | $109M | – | – |
| CRYSVITA - Product sales - Latin America and TürkiyeNot provided. | $41M | – | – |
| CRYSVITA - Royalty revenue - U.S. and CanadaNot provided. | $61M | – | – |
| CRYSVITA - Royalty revenue - EuropeNot provided. | $7M | – | – |
| DOJOLVINot provided. | $30M | – | – |
| EVKEEZAIncreased demand from new country launches and early access. | $24M | – | – |
| MEPSEVIINot provided. | $10M | – | – |
Full year 2026 and 2027 outlook
- RevenueFull year 2026 total revenue of $730 million to $760 million, excluding revenue from new product launches; full year 2026 CRYSVITA revenue of $500 million to $520 million; full year 2026 DOJOLVI revenue of $100 million to $110 million
- Operating expenses2027 R&D expenses of less than $350 million; 2027 SG&A expenses of less than $375 million
- NoteFull-year GAAP profitability in 2027 and going forward.
- NoteFourth quarter 2026 financial results are expected to include approximately $25 million of severance and other non-recurring restructuring charges.
- NoteThe reduction in force is expected to be substantially completed by the end of 2026.
- NoteNet proceeds from both PRV sales are expected to be approximately $350 million.
- NoteDTX301 Phase 3 Enh3ance data are expected in the first half of 2027.
What drove it
- Third-quarter total revenue was $173 million, including $109 million of CRYSVITA revenue, $30 million of DOJOLVI revenue, $24 million of EVKEEZA revenue and $10 million of MEPSEVII revenue.
- EVKEEZA revenue was driven by increased demand from new country launches and early access.
- FDA granted accelerated approval for GENGLYCOS in August 2026 and standard full approval for FAYUVI in September 2026.
- The company is focused on commercial execution, successful GENGLYCOS and FAYUVI launches, and continued growth in current product revenues.
- The company initiated substantial headcount and expense reductions after completing late-stage development programs.
Concerns
- The company reported a net loss of $(118) million for the third quarter and a net loss of $(395) million for the nine months ended September 30, 2026.
- Total stockholders' deficit was $(376) million as of September 30, 2026.
- The company is reducing headcount by approximately 20%, with a revised workforce of approximately 1,000 employees.
- The company is completing the wind-down of all ongoing GTX-102 studies and terminating UX701 after the program did not meet criteria to advance to the pivotal Phase 3 stage.
- The FAYUVI PRV sale is expected to close later in November 2026, and the company states that PRV sales may not close on the expected timeline or at all.
- GENGLYCOS received accelerated approval and is subject to confirmatory study requirements; the FDA may withdraw accelerated approval if confirmatory studies do not verify clinical benefit.
What to watch
- Closing of the FAYUVI PRV sale and receipt of expected net proceeds from both PRV sales.
- Execution of the approximately 20% headcount reduction, targeted expense reductions and expected fourth-quarter restructuring charges.
- Commercial launches and demand for GENGLYCOS and FAYUVI.
- Delivery of the second primary endpoint data from the DTX301 Phase 3 Enh3ance study in the first half of 2027.
- Regulatory engagement to determine whether there is a potential path forward for UX143.
- Progression of UX016, for which dosing is to be initiated soon and the Phase 1/2 study is funded through clinical proof-of-concept by an external venture philanthropy agreement.
Balance sheet and cash flow
- Cash, cash equivalents, and marketable securities were $401 million as of September 30, 2026, compared with $737 million as of December 31, 2025.
- Working capital was $155 million as of September 30, 2026, compared with $567 million as of December 31, 2025.
- Total assets were $1,187 million as of September 30, 2026, compared with $1,532 million as of December 31, 2025.
- Total stockholders' deficit was $(376) million as of September 30, 2026, compared with $(80) million as of December 31, 2025.
- Net cash used in operations was $43 million for the three months ended September 30, 2026.
- The GENGLYCOS PRV was sold for $210 million.
- The FAYUVI PRV is under a definitive agreement for $203 million.
- The two PRVs are under agreement for a combined sales price of $413 million. Net proceeds from both sales are expected to be approximately $350 million.
Analysis
Ultragenyx reported third-quarter total revenue of $173 million, compared with $160 million in the prior-year quarter. Product sales were $105 million and royalty revenue was $68 million. CRYSVITA generated $109 million, described as consistent with expected ordering patterns, while DOJOLVI contributed $30 million. EVKEEZA revenue was $24 million and was driven by increased demand from new country launches and early access. Nine-month total revenue was $523 million, compared with $466 million in the prior-year period.
The loss narrowed during the quarter as research and development expense declined to $154 million from $216 million, more than offsetting higher cost of sales and selling, general and administrative expense. Total operating expenses were $283 million, compared with $331 million, and loss from operations was $(110) million, compared with $(171) million. Net loss was $(118) million, or $(1.16) per share basic and diluted, versus $(180) million, or $(1.81) per share. The company also recorded $34 million of non-cash stock-based compensation in the quarter.
Management is undertaking a material reshaping of the cost base. The company expects to reduce headcount by approximately 20% to a revised workforce of approximately 1,000 employees, reduce 2027 R&D expenses to less than $350 million, and reduce 2027 SG&A expenses to less than $375 million. It is winding down GTX-102 studies, terminating UX701, reducing its real estate footprint, and expects approximately $25 million of severance and other non-recurring restructuring charges in fourth-quarter 2026 results. The company continues to anticipate full-year GAAP profitability in 2027 and going forward.
Liquidity and near-term funding are also central to the reported period. Cash, cash equivalents, and marketable securities were $401 million as of September 30, 2026, while net cash used in operations was $43 million for the quarter. The GENGLYCOS PRV sale closed for $210 million, and the FAYUVI PRV is under agreement for $203 million, with combined expected net proceeds of approximately $350 million. The company reaffirmed full-year 2026 total revenue guidance of $730 million to $760 million, excluding new product launches, as well as CRYSVITA and DOJOLVI revenue guidance.
The operating focus is shifting toward execution of GENGLYCOS and FAYUVI launches, growth of existing products, and a smaller targeted pipeline. Upcoming development priorities include first-half 2027 data from the DTX301 Phase 3 Enh3ance study and regulatory discussions on UX143. The reported period also includes meaningful pipeline contraction through the UX701 termination and GTX-102 wind-down, while GENGLYCOS carries confirmatory study requirements associated with its accelerated approval.
Management, verbatim
We received two BLA approvals from the FDA within one month for our first gene therapy treatments and the launches are progressing well with growing demand for these products.
Emil D. Kakkis, M.D., Ph.D., chief executive officer and president
With substantial reductions in headcount and expenses, combined with two launches and continued growth in our base business, we expect meaningful profitability in 2027 and going forward.
Emil D. Kakkis, M.D., Ph.D., chief executive officer and president
Not in the filing
stated, not guessed- Gross margin was not reported.
- Non-GAAP revenue, earnings, operating income, net income, EPS, or cash flow measures were not reported.
- Prior-quarter comparisons were not reported for the financial statement metrics.
- Percentage year-over-year and quarter-over-quarter changes were not reported for the financial statement and product revenue metrics.
- Free cash flow, capital expenditures, and investing cash flow were not reported.
- Debt balances and maturities were not reported.
- Share repurchases and dividends were not reported.
- A previous outlook section was not provided, so prior-guidance comparisons cannot be made.
- A tax rate was not reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Ultragenyx (NASDAQ:RARE) filed an 8‑K with Q3 2026 financials, two FDA approvals, and a restructuring plan.
Ticker impact
Ultragenyx reported Q3 2026 results, announced expense reductions and reaffirmed 2026 revenue and 2027 profitability guidance.
likely upward pressure as investors price in lower costs and confirmed profitability path
The 8‑K provides fresh revenue numbers, two FDA approvals and a clear cost‑reduction plan, all of which are new and material for a micro‑cap biotech.
Market effects
Reinforces optimism for rare‑disease biotech sector after FDA approvals and cost cuts.
US biotech investors may re‑allocate to RARE given its improved outlook.
Limited to biotech niche; no broad market effect.
Counterpoint
Cost cuts could signal underlying revenue pressure; investors may wait for Q4 results before buying.
Key entities
- companyUltragenyx Pharmaceutical Inc.
Biopharma focused on rare genetic diseases, ticker RARE.
